The standard US military treatment for nerve agent exposure is application of up to three autoinjectors, each containing atropine sulfate and2-pralidoxime, to counteract symptoms of nerve agent intoxication and restore acetylcholinesterase activity. This treatment increases survivalrates after nerve agent exposure, however, seizures resulting from nerve agent poisoning are a common symptom that can prolong recoveryand reduce survival rates. The motion-sickness drug scopolamine hydrobromide, has been demonstrated as an effective treatment forreducing seizures and enhancing survival and recovery from nerve agent exposure. A single autoinjector with a combined formulation ofatropine and scopolamine would be extremely beneficial to our warfighters and first responders; however, a stable dual formulation ofatropine and scopolamine has not been demonstrated. We propose to develop stable dual formulations of atropine sulfate and scopolaminehydrobromide. The dual formulations containing both drugs will be stable for a minimum of 2 years with a volume of 2 mL or less.
